rs199814742
Positions:
Variant summary
Our verdict is Benign. Variant got -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBS1BS2
The NM_001323289.2(CDKL5):c.145+17A>G variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00558 in 623,579 control chromosomes in the GnomAD database, including 30 homozygotes. There are 1,116 hemizygotes in GnomAD. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).
Frequency
Genomes: 𝑓 0.0036 ( 2 hom., 118 hem., cov: 21)
Exomes 𝑓: 0.0060 ( 28 hom. 998 hem. )
Consequence
CDKL5
NM_001323289.2 intron
NM_001323289.2 intron
Scores
2
Clinical Significance
Conservation
PhyloP100: -0.180
Genes affected
CDKL5 (HGNC:11411): (cyclin dependent kinase like 5) This gene is a member of Ser/Thr protein kinase family and encodes a phosphorylated protein with protein kinase activity. Mutations in this gene have been associated with X-linked infantile spasm syndrome (ISSX), also known as X-linked West syndrome, and Rett syndrome (RTT). Alternate transcriptional splice variants have been characterized. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -20 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.91).
BP6
Variant X-18564539-A-G is Benign according to our data. Variant chrX-18564539-A-G is described in ClinVar as [Likely_benign]. Clinvar id is 136709.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chrX-18564539-A-G is described in Lovd as [Benign]. Variant chrX-18564539-A-G is described in Lovd as [Likely_benign].
BS1
Variant frequency is greater than expected in population nfe. gnomad4 allele frequency = 0.00357 (381/106814) while in subpopulation NFE AF= 0.00448 (233/52042). AF 95% confidence interval is 0.00401. There are 2 homozygotes in gnomad4. There are 118 alleles in male gnomad4 subpopulation. Median coverage is 21. This position pass quality control queck.
BS2
High Homozygotes in GnomAd4 at 2 XL gene
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CDKL5 | NM_001323289.2 | c.145+17A>G | intron_variant | ENST00000623535.2 | NP_001310218.1 | |||
CDKL5 | NM_001037343.2 | c.145+17A>G | intron_variant | NP_001032420.1 | ||||
CDKL5 | NM_003159.3 | c.145+17A>G | intron_variant | NP_003150.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CDKL5 | ENST00000623535.2 | c.145+17A>G | intron_variant | 1 | NM_001323289.2 | ENSP00000485244.1 |
Frequencies
GnomAD3 genomes AF: 0.00359 AC: 383AN: 106819Hom.: 2 Cov.: 21 AF XY: 0.00397 AC XY: 119AN XY: 29959
GnomAD3 genomes
AF:
AC:
383
AN:
106819
Hom.:
Cov.:
21
AF XY:
AC XY:
119
AN XY:
29959
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00980 AC: 645AN: 65810Hom.: 11 AF XY: 0.0124 AC XY: 228AN XY: 18352
GnomAD3 exomes
AF:
AC:
645
AN:
65810
Hom.:
AF XY:
AC XY:
228
AN XY:
18352
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00600 AC: 3101AN: 516765Hom.: 28 Cov.: 8 AF XY: 0.00888 AC XY: 998AN XY: 112335
GnomAD4 exome
AF:
AC:
3101
AN:
516765
Hom.:
Cov.:
8
AF XY:
AC XY:
998
AN XY:
112335
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.00357 AC: 381AN: 106814Hom.: 2 Cov.: 21 AF XY: 0.00394 AC XY: 118AN XY: 29966
GnomAD4 genome
AF:
AC:
381
AN:
106814
Hom.:
Cov.:
21
AF XY:
AC XY:
118
AN XY:
29966
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Benign/Likely benign
Submissions summary: Benign:8Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not specified Benign:4
Benign, no assertion criteria provided | clinical testing | Genome Diagnostics Laboratory, University Medical Center Utrecht | - | - - |
Benign, no assertion criteria provided | curation | RettBASE | May 09, 2014 | - - |
Benign, criteria provided, single submitter | clinical testing | GeneDx | Mar 15, 2012 | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. - |
Benign, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Jun 29, 2015 | - - |
Developmental and epileptic encephalopathy, 2 Benign:2
Likely benign, no assertion criteria provided | clinical testing | Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen | - | - - |
Likely benign, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | May 03, 2022 | - - |
CDKL5 disorder Benign:1
Benign, criteria provided, single submitter | curation | Centre for Population Genomics, CPG | Jul 04, 2024 | This variant has been collected from RettBASE and curated to current modified ACMG/AMP criteria. Based on the classification scheme defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like Disorders Specifications to the ACMG/AMP Variant Interpretation Guidelines VCEP 3.0, this variant is classified as benign. At least the following criteria are met: The allele frequency of this variant in at least one population in gnomAD is higher than the 0.03% threshold defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like Disorders VCEP 3.0 (BA1). The computational splicing predictor SpliceAI does not support significant splicing alteration (score of <=0.1) (BP4). - |
Developmental and epileptic encephalopathy, 2;CN128785:Angelman syndrome-like Benign:1
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 01, 2024 | - - |
not provided Other:1
not provided, flagged submission | literature only | RettBASE | - | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at